| AEs | adverse events |
| AE-QoL | angioedema quality of life questionnaire |
| BTK | Bruton’s tyrosine kinase |
| CI | confidence interval |
| CRS | chronic rhinosinusitis |
| CU | chronic urticaria |
| CU-Q2oL | chronic urticaria quality of life questionnaire |
| CSU | chronic spontaneous urticaria |
| FDA | Food and Drug Administration |
| EMA | European Medicine Agency |
| FcεRI | high affinity IgE receptor |
| DLQI | dermatology life quality index |
| H1AH | H1 antihistamines |
| H2AH | H2 antihistamines |
| HRQoL | health-related quality of life |
| HSS7 | weekly hives severity score |
| IgE | immunoglobulin E |
| IgG | immunoglobulin G |
| ISI | insomnia severity index |
| ISS7 | weekly itch severity score |
| LTRAs | leukotriene receptor antagonists |
| mAbs | monoclonal antibodies |
| OR | odds ratio |
| RDBPCT | randomized double-blind placebo controlled trial |
| RCTs | randomized controlled trials |
| SAEs | serious adverse events |
| TPO | thyroperoxidase |
| TSLP | anti-thymic stromal lymphopoietin |
| UAS7 | weekly urticaria activity score |
| Versus | vs. |
| WPAI | work productivity and activity impairment |